References
- Dember LM, Sanchorawala V, Seldin DC, Wright DG, Lavalley M, Berk JL, Falk RH, Skinner M. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease. Ann Intern Med 2001;134:746–753.
- Seldin DC, Anderson JJ, Sanchorawala V, Malek K, Wright DG, Quillen K, Finn KT, Berk JL, Dember LM, Falk RH, Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood 2004;104:1888–1893.
- Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, Anderson JJ, O'Hara C, Finn KT, Libbey CA, High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004;140:85–93.
- Seldin DC, Anderson JJ, Skinner M, Malek K, Wright DG, Quillen K, Finn K, Oran B, Sanchorawala V. Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65. Blood 2006;108:3945–3947.
- Dey BR, Chung SS, Spitzer TR, Zheng H, Macqillivray TE, Seldin DC, McAfee S, Ballen K, Attar E, Wang T, Cardiac transplantation followed by dose-intensive melphalam and autologous stem-cell transplantation for light-chain amyloidosis and heart failure. Transplantation 2010;90:905–911.
- Casserly LF, Fadia A, Sanchorawala V, Seldin DC, Wright DG, Skinner M, Dember LM. High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease. Kidney Int 2003;63:1051–1057.
- McDiarmid S, Hutton B, Atkins H, Bence-Bruckler I, Bredeson C, Sabri E, Huebsch L. Performing allogeneic and autologous hematopoietic SCT in the outpatient setting: effects on infectious complications and early transplant outcomes. Bone Marrow Transplant 2010;45:1220–1226.